Drug Profile
Paclitide
Latest Information Update: 27 Feb 2019
Price :
$50
*
At a glance
- Originator Fannin Bioscience
- Developer Hefei Anderson Pharma
- Class Antineoplastics; Diterpenes; Drug conjugates; Paclitaxels; Peptides
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 27 Feb 2019 Discontinued - Phase-II for Breast cancer in China (IV)